- Strategic Partnership Strengthens Gilead’s Inflammation Research Portfolio with the Addition of LEO Pharma’s Preclinical Oral STAT6 Program, Including Targeted Protein Degraders --
-- Gilead Will Have Exclusive Global Rights to the STAT6 Program, and LEO Pharma Will Have the Option to Co-Commercialize for Dermatology Indications Outside the U.S. --
-- LEO Pharma to Maintain Global Rights to Topical Formulations of the STAT6 Program in Dermatology --
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.